ARMP armatapharma.com: Rasio total nilai perusahaan marang pendapatan

Armata Pharmaceuticals (ARMP) is developing innovative treatments against superbugs based on unique patents, while strict financial control by the Innoviva fund minimizes expenditure risks. The enterprise value-to-annual revenue multiple visualizes this trend, where the 45574.83 mark reflects the latest data. Stringent FDA requirements and testing costs limit competitor access, maintaining the asset's speculative nature until trials are completed.
Armata Pharmaceuticals Inc - rincian analitis lan metrik utama (ARMP)

EV/Sales (co) measures the total enterprise value, including debt, relative to annual revenue to determine the market revaluation of assets. Investors utilize this multiple to analyze revenue generation efficiency relative to capitalization. The current enterprise value-to-sales level reflects the speculative nature of the Armata Pharmaceuticals (ARMP) valuation. High development costs for bacteriophages make this metric sensitive to Phase 2 expectations, and a compression of this indicator could signal a reassessment of R&D risks.